Detalhe da pesquisa
1.
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial.
Europace
; 23(10): 1539-1547, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128075
2.
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Eur Heart J
; 41(41): 4037-4046, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32984892
3.
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
Am Heart J
; 219: 21-30, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31710841
4.
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis.
Europace
; 22(6): 870-877, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32215649
5.
Filling an Important Knowledge Gap: The DOAC Score.
Circulation
; 148(12): 947-949, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621202
6.
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.
Circulation
; 138(9): 889-897, 2018 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29678813
7.
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
Am Heart J
; 213: 81-90, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31129441
8.
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Europace
; 21(11): 1633-1638, 2019 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31436835
9.
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Eur Heart J
; 39(32): 2959-2971, 2018 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659797
10.
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
Eur Heart J
; 39(6): 477-485, 2018 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29069359
11.
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.
Europace
; 20(12): 1936-1943, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29947751
12.
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
Europace
; 20(2): 253-262, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28520924
13.
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
J Thromb Thrombolysis
; 46(4): 435-439, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30051164
14.
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
Eur Heart J
; 38(12): 852-859, 2017 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26848149
15.
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
Eur Heart J
; 38(12): 860-868, 2017 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26848150
16.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Circulation
; 134(8): 589-98, 2016 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496855
17.
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
Circulation
; 134(22): 1697-1707, 2016 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27569438
18.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Lancet
; 387(10035): 2302-2311, 2016 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27056738
19.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Lancet
; 388(10055): 1995-2003, 2016 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27590218
20.
The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Am Heart J
; 193: 16-22, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29129251